RITUXIMAB BASED COMBINATION CHEMOTHERAPY WITHOUT ETOPOSIDE IN AGGRESSIVE B- CELL NON-HODGKIN LYMPHOMA IN CHINESE CHILDREN: MULTIPLE CENTER EXPERIENCE (SIOP 2026) - Oct 23, 2026 - Abstract #Shift 02 - 181; Pres time: Sep 17, 2026; Location: Exhibition Area; "Etoposide-free, rituximab-based intensive chemotherapy is highly effective and tolerable in Chinese children with aB-NHL, achieving excellent survival outcomes while potentially avoiding etoposide-related secondary malignancies. CNS involvement remains a significant risk factor for relapse, warranting intensified strategies. Rituximab-induced B-cell and humoral immune suppression requires vigilant monitoring and supportive care."
Clinical • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Burkitt Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hepatitis B • Hepatology • High-grade B-cell lymphoma • Infectious Disease • Leukemia • Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin's Lymphoma • Primary Mediastinal Large B-Cell Lymphoma • Septic Shock • CD20
|
|
Jianwen Xiao1; Yuxia Guo1; Min Zhou2; Yueting Long3
|